The UK will become the first country to launch a clinical trial of a new coronavirus antibody treatment targeting people with weakened immune systems who cannot be vaccinated.
A volunteer in Manchester will be the first person in the world to receive AstraZeneca’s new “antibody cocktail” as part of a test to see if it will prevent it. COVID-19 For years.
The clinical trial program will recruit 5,000 participants, including 1,000 from nine sites in the UK.
The goal of the experiment was to evaluate the safety and efficacy of a combination of two long-acting monochromatic antibodies – man-made proteins that act like natural human antibodies in the immune system.
Sir Men Pangalos, executive vice president of biopharmaceuticals R&D in AstraZeneca, said the treatment could be given by injection or intravenously.
“There are going to be a significant number of people here – even in a world where vaccines are highly effective – who do not respond to vaccines or will not actually receive the vaccine,” he added.
“So it’s also important to have exclusive antibodies as potential therapeutics.”
The UK government has a policy agreement to protect access to ten million doses of antibody compounds, dubbed AZD424442, if it succeeds in a three-step trial.
The trial puts them at risk of enrolling adults Coronavirus Infections or those who are more likely to have an inadequate response to vaccinations will include people in health care and care home settings.
Preliminary results from the randomized controlled trial are expected to be released in the first half of 2021, although the test will last 12 months.
:: Subscribe to Daily Podcasts on Apple Podcasts, Google Podcasts, Spotify, Sprayer
While it is unclear how much it will cost to treat antibodies, Sir Manny said it would be “more expensive than a vaccine”, but added “we hope it can be made effective.”
Business Secretary Alok Sharma said: “As we move closer to a COVID-19 vaccine, we must continue our clinical trials for new and alternative treatments that protect our vulnerable, especially those who cannot receive the vaccine.”